However, current methods of evidence collection-such as clinical trials-do not account for these data elements, nor time horizons. As discussed in the previous 2 sections of this supplement, 1,2 the burden of Alzheimer’s escalates over the course of the disease and extends beyond direct medical costs, affecting caregivers, long-term care systems, economies, and society as a whole. There is a pressing need for payers, value assessors, and the broader Alzheimer’s community to integrate real-world evidence into long-term value assessments. The Need for Long-Term Value Demonstration in Alzheimer’s Disease Neumann, ScD, Center for the Evaluation of Value and Risk in Health, Tufts University School of Medicine, Boston, MA, USA Paola Barbarino, MA, Chief Executive Officer, Alzheimer’s Disease International, London, England, UK Anders Gustavsson, PhD, MSc, Partner, Quantify Research Affiliate, Karolinska Institutet, Stockholm, Sweden Peter J.
0 kommentar(er)
